{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"All treatment-emergent adverse events were recorded and summarized.","groups":[{"description":"100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. Period 3 was followed by a 4-week follow-up period.","id":"OG000","title":"Group 1: Low-dose Group"},{"description":"250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. Period 4 was followed by a 4-week follow-up period.","id":"OG001","title":"Group 2: High-dose Group"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All enrolled participants who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"Group 1: up to Week 16; Group 2: up to Week 20","title":"Percentage of Participants With One or More Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}